Register to leave comments

  • News bot Jan. 9, 2026, 11:19 a.m.

    📋 HAEMONETICS CORPORATION (HAE) - Clinical Trial Update

    Filing Date: 2026-01-09

    Accepted: 2026-01-09 06:17:23

    Event Type: Clinical Trial Update

    Event Details:

    Haemonetics Corporation (HAE) Announces Clinical Trial Update Haemonetics Corporation (HAE) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: approval, need
    • Diseases/Conditions: pre-close, percutaneous vessel closure
    • Collaboration: PerQseal

    🔬 Clinical Development Pipeline (HAEMONETICS CORPORATION):

    Product Type Development Stage Therapeutic Area Source
    BIO 300 Oral Suspension DRUG Phase PHASE1 Healthy Volunteer Study ClinicalTrials.gov
    Clopidogrel and proton pump inhibitors DRUG Phase PHASE4 30 Healthy People ClinicalTrials.gov
    OrthoPAT DEVICE Phase PHASE4 Osteoarthritis ClinicalTrials.gov
    Erythropoietin and drain device OTHER Phase PHASE4 Osteoarthritis ClinicalTrials.gov
    Erythropoietin and OrthoPAT OTHER Phase PHASE4 Osteoarthritis ClinicalTrials.gov
    Post-operative drain device DEVICE Phase PHASE4 Osteoarthritis ClinicalTrials.gov
    erythropoietin DRUG Phase PHASE4 Osteoarthritis ClinicalTrials.gov
    erythropoietin and cell saver OTHER Phase PHASE4 Osteoarthritis ClinicalTrials.gov
    OrthoPat Advance DEVICE Preclinical Transmission, Blood, Recipient/Donor ClinicalTrials.gov
    RapidTEG test PROCEDURE Preclinical Coagulopathy ClinicalTrials.gov
    Isotonic Saline DRUG Phase PHASE2 Postpartum Haemorrhage ClinicalTrials.gov
    Fibrinogen Concentrate DRUG Phase PHASE2 Postpartum Haemorrhage ClinicalTrials.gov
    BIO 300 Capsules DRUG Phase PHASE1 Acute Radiation Syndrome ClinicalTrials.gov
    Aspirin DRUG Phase PHASE4 Primary Total Hip and Knee Arthroplasty ClinicalTrials.gov
    Pneumatic compression stockings DEVICE Phase PHASE4 Primary Total Hip and Knee Arthroplasty ClinicalTrials.gov
    Arixtra DRUG Phase PHASE4 Primary Total Hip and Knee Arthroplasty ClinicalTrials.gov
    Placebo DRUG Phase PHASE2 Alzheimer's Disease ClinicalTrials.gov
    Drug: NIC5-15 DRUG Phase PHASE2 Alzheimer's Disease ClinicalTrials.gov
    7-Keto Dehydroepiandrosterone DRUG Phase PHASE2 PTSD ClinicalTrials.gov
    Cilostazol 100mg DRUG Approved Coronary Heart Disease ClinicalTrials.gov
    Aspirin 100mg DRUG Approved Coronary Heart Disease ClinicalTrials.gov
    Clopidogrel 150mg DRUG Approved Coronary Heart Disease ClinicalTrials.gov
    Clopidogrel 75mg DRUG Approved Coronary Heart Disease ClinicalTrials.gov
    NIC5-15 DRUG Phase PHASE2 Alzheimer Disease ClinicalTrials.gov
    Blood product transfusion based on rapid thrombelastography (r-TEG) results. BIOLOGICAL Approved Acute Coagulopathy ClinicalTrials.gov
    Blood product transfusion based on conventional coagulation tests. BIOLOGICAL Approved Acute Coagulopathy ClinicalTrials.gov
    TEG6s DOAC Cartridge DEVICE Preclinical DOAC Eligible Subjects ClinicalTrials.gov
    Current Plasma Collection Approach DEVICE Approved Apheresis Related Hypotension ClinicalTrials.gov
    Updated Plasma Collection Feature DEVICE Approved Apheresis Related Hypotension ClinicalTrials.gov
    AS-3 (Control) DRUG Phase PHASE1 Blood Donors ClinicalTrials.gov
    SOLX (Investigational) DRUG Phase PHASE1 Blood Donors ClinicalTrials.gov
    Kawasumi (Needle Assembly) DEVICE Approved Transmission, Blood, Recipient/Donor ClinicalTrials.gov
    POLFA (Needle Assembly) DEVICE Approved Transmission, Blood, Recipient/Donor ClinicalTrials.gov
    Radiotherapy RADIATION Phase PHASE1 Carcinoma, Non-Small-Cell Lung ClinicalTrials.gov
    Carboplatin DRUG Phase PHASE1 Carcinoma, Non-Small-Cell Lung ClinicalTrials.gov
    Paclitaxel DRUG Phase PHASE1 Carcinoma, Non-Small-Cell Lung ClinicalTrials.gov
    BIO 300 Oral Powder DRUG Phase PHASE1 Acute Radiation Syndrome ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Haemonetics Corporation
    • CIK: 0000313143
    • Ticker Symbol: HAE
    • Period End Date: 2026-01-09
    • Document Type: 8-K